{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:30:15Z","timestamp":1785933015139,"version":"3.56.0"},"reference-count":86,"publisher":"Informa UK Limited","issue":"1","funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["Grant Agreement No. 693398-ILID"],"award-info":[{"award-number":["Grant Agreement No. 693398-ILID"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2022,1,2]]},"DOI":"10.1080\/14737175.2021.2001328","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T20:00:14Z","timestamp":1635883214000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children"],"prefix":"10.1080","volume":"22","author":[{"given":"Jordan L.","family":"Clay","sequence":"first","affiliation":[{"name":"University of Kentucky Comprehensive Epilepsy Program, Department of Neurology, University of Kentucky College of Medicine, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan B.","family":"Fountain","sequence":"additional","affiliation":[{"name":"F.E. Dreifuss Comprehensive Epilepsy Program, Department of Neurology, University of Virginia Health Systems, Charlottesville, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,12,19]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13121"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1018"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.03.023"},{"key":"cit0004","first-page":"261","volume":"34","author":"Meldrum BS.","year":"1983","journal-title":"Adv Neurol"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.3.735"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.4.1029"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1159\/000111873"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14607"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02562.x"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12269"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.05.007"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2003.63702.x"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1542\/peds.83.3.323"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00071-5"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2019.09.001"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1323873"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597-16.1.48"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809173391202"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa002141"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03235.x"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/0887-8994(95)00044-G"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66909-7"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2008.01097.x"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12058"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(03)00036-4"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.2625"},{"issue":"4","key":"cit0027","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/j.1875-9114.1996.tb03646.x","volume":"16","author":"Boucher BA","year":"1996","journal-title":"Pharmacotherapy"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.07.016"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25249"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2021.01.014"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.28501.x"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003690"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03340320048027"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6_Suppl_1.8S"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1988.00380060093019"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03330300046032"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6_Suppl_1.3S"},{"issue":"5","key":"cit0038","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/j.1875-9114.1996.tb02996.x","volume":"16","author":"Boucher BA","year":"1996","journal-title":"Pharmacotherapy"},{"key":"cit0039","first-page":"678","volume-title":"Wyllie\u2019s treatment of epilepsy: principles and practice","author":"Conway JM","year":"2020","edition":"7"},{"key":"cit0040","unstructured":"Pfizer Inc. CEREBYX\u00ae - fosphenytoin sodium injection, solution. US prescribing information. 2021 [cited 2021 Apr 14]. Available from: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=749"},{"key":"cit0041","unstructured":"US Food and Drug Administration. Drug databases. Drugs@FDA. Abbreviated New Drug Application (ANDA): 078126. 2021. [cited 2021 Apr 14]. Available from: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=749"},{"key":"cit0042","unstructured":"Sedor Pharmaceuticals LLC. SESQUIENT - fosphenytoin sodium injection, solution. US prescribing information. 2020 [cited 2021 Apr 14]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/210864s000lbl.pdf"},{"key":"cit0043","first-page":"565","volume-title":"Antiepileptic drugs","author":"DeLorenzo R","year":"2002","edition":"5"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(03)00099-2"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-012-0105-x"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.3_Part_1.456"},{"key":"cit0047","first-page":"139","volume":"25","author":"Runge JW","year":"1995","journal-title":"Ann Emerg Med"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6_Suppl_1.14S"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-015-0490-z"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1994.tb02788.x"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905795"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30611-5"},{"key":"cit0053","first-page":"367","volume":"14","author":"Andrews CO","year":"1994","journal-title":"Pharmacotherapy"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342010-00002"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015940527815"},{"issue":"1","key":"cit0056","first-page":"51","volume":"88","author":"Lai CM","year":"1995","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1990.tb06111.x"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb03124.x"},{"issue":"8","key":"cit0059","first-page":"194","volume":"38","author":"Morton LD","year":"1997","journal-title":"Epilepsia"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00778.x"},{"key":"cit0061","first-page":"212","volume":"53","author":"Eldon MA","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.20800.x"},{"issue":"4","key":"cit0063","first-page":"SI80","volume":"20","author":"Eldon MA","year":"1993","journal-title":"Can J Neurol Sci"},{"key":"cit0064","doi-asserted-by":"crossref","first-page":"A245","DOI":"10.1212\/WNL.46.6_Suppl_1.17S","volume":"46","author":"Ramsay RE","year":"1996","journal-title":"Neurology"},{"issue":"4","key":"cit0065","first-page":"A202","volume":"45","author":"Fischer J","year":"1995","journal-title":"Neurology"},{"issue":"2","key":"cit0066","first-page":"A308","volume":"43","author":"Wilder BJ","year":"1993","journal-title":"Neurology"},{"issue":"4","key":"cit0067","first-page":"A249","volume":"45","author":"Ramsay E","year":"1995","journal-title":"Neurology"},{"issue":"14","key":"cit0068","first-page":"90","volume":"36","author":"Allen FH","year":"1995","journal-title":"Epilepsia"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01829.x"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.4103\/jpn.JPN_109_19"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-020-03221-2"},{"key":"#cr-split#-cit0072.1","unstructured":"Pfizer, Inc. An open-label, safety, tolerance, and pharmacokinetic study of intravenous and intramuscular fosphenytoin (Cerebyx\u00ae) in children (Protocol 982-028). [Internet]. [Updated 2011 Nov 21"},{"key":"#cr-split#-cit0072.2","unstructured":"cited 2021 May 17]. Available from: http:\/\/art45-paediatric-studies-docs.ema.europa.eu\/GROUP%20F\/fosphenytoin%20sodium\/982-028%20EMA%20Pediatrics%20Web%20Synopsis.pdf"},{"key":"cit0073","unstructured":"Sheridan PH. Clinical review, pediatric supplement NDA 20550 S003, Cerebyx (intravenous fosphenytoin sodium). Silver Spring (MD): US Food and Drug Administration; [internet] 2017 (FDA publication; Ref ID: 4057517). [Cited 2021 May 17]. Available from: https:\/\/www.fda.gov\/media\/103863\/download"},{"key":"cit0074","unstructured":"Lee R, Kim IE, McCulley LV, et al. Pediatric postmarketing pharmacovigilance, cerebyx (Fosphenytoin Sodium). Silver Spring (MD): US Food and Drug Administration; [internet] (FDA publication; Ref ID: 4453265). 2019 [Cited 2021 May 17]. Available from: https:\/\/www.fda.gov\/media\/130822\/download"},{"key":"#cr-split#-cit0075.1","unstructured":"Electronic medicine compendium [Internet]. Surrey (UK): Datapharm Ltd. [Updated 2020 03"},{"key":"#cr-split#-cit0075.2","unstructured":"Cited 2021 May 8]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/2260\/smpc"},{"key":"cit0076","unstructured":"European Medicines Agency. List of nationally authorised medicinal products, active substance: fosphenytoin. [Internet]. Amsterdam (ND): Human Medicines Evaluation Division; [Updated 2021 Mar 25; Cited 2021 May 18]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/fosphenytoin-list-nationally-authorised-medicinal-products-psusa\/00001476\/202008_en.pdf"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2007.04.012"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80051-8"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.10.844.31556"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2003.10.011"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1179\/016164102101200834"},{"key":"cit0082","unstructured":"Neurological Emergencies Treatment Trials (NETT) Network. Home page. [Internet]. Ann Arbor (MI): University of Michigan; National Institute of Neurological Disorders and Stroke; [Cited 2021 May 19]. Available from: https:\/\/nett.umich.edu\/"},{"key":"cit0083","unstructured":"American Epilepsy Society. Clinical guidance. [Internet]. Chicago (IL); [Cited 2021 May 19]. Available from: https:\/\/www.aesnet.org\/clinical-care\/clinical-guidance"},{"key":"cit0084","unstructured":"Epilepsy Foundation of America. Resource library. [Internet]. Bowie (MD). [Cited 2021 May 19]. Available from: https:\/\/www.epilepsy.com\/living-epilepsy\/epilepsy-and\/professional-health-care-providers\/resource-library"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2021.2001328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T04:50:11Z","timestamp":1699764611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2021.2001328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,19]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,2]]}},"alternative-id":["10.1080\/14737175.2021.2001328"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2021.2001328","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}